vs
Side-by-side financial comparison of OPKO HEALTH, INC. (OPK) and Opera Ltd (OPRA). Click either name above to swap in a different company.
OPKO HEALTH, INC. is the larger business by last-quarter revenue ($148.5M vs $142.7M, roughly 1.0× Opera Ltd). Opera Ltd runs the higher net margin — 12.8% vs -21.1%, a 33.9% gap on every dollar of revenue.
OPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".
Opera is a multinational technology corporation headquartered in Oslo, Norway, with additional offices in Europe, China, and Africa. Opera offers a range of products and services that include PC and mobile web browsers, GameMaker and gaming portals, the Opera News content recommendation products, the Opera Ads platform, and a number of Web3 and e-commerce products and services. The company's total user base is 296 million monthly active users.
OPK vs OPRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | ||
|---|---|---|
| Revenue | $148.5M | $142.7M |
| Net Profit | $-31.3M | $18.3M |
| Gross Margin | 43.1% | — |
| Operating Margin | -25.8% | 14.8% |
| Net Margin | -21.1% | 12.8% |
| Revenue YoY | -19.2% | — |
| Net Profit YoY | -322.8% | — |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.5M | — | ||
| Q3 25 | $151.7M | — | ||
| Q2 25 | $156.8M | — | ||
| Q1 25 | $150.0M | $142.7M | ||
| Q4 24 | $183.6M | — | ||
| Q3 24 | $173.6M | — | ||
| Q2 24 | $182.2M | $211.6M | ||
| Q1 24 | $173.7M | — |
| Q4 25 | $-31.3M | — | ||
| Q3 25 | $21.6M | — | ||
| Q2 25 | $-148.4M | — | ||
| Q1 25 | $-67.6M | $18.3M | ||
| Q4 24 | $14.0M | — | ||
| Q3 24 | $24.9M | — | ||
| Q2 24 | $-10.3M | $34.1M | ||
| Q1 24 | $-81.8M | — |
| Q4 25 | 43.1% | — | ||
| Q3 25 | 32.9% | — | ||
| Q2 25 | 31.5% | — | ||
| Q1 25 | 28.4% | — | ||
| Q4 24 | 46.1% | — | ||
| Q3 24 | 23.1% | — | ||
| Q2 24 | 28.4% | — | ||
| Q1 24 | 24.2% | — |
| Q4 25 | -25.8% | — | ||
| Q3 25 | 31.7% | — | ||
| Q2 25 | -38.3% | — | ||
| Q1 25 | -44.8% | 14.8% | ||
| Q4 24 | -18.0% | — | ||
| Q3 24 | 8.2% | — | ||
| Q2 24 | -33.9% | 19.6% | ||
| Q1 24 | -41.2% | — |
| Q4 25 | -21.1% | — | ||
| Q3 25 | 14.3% | — | ||
| Q2 25 | -94.7% | — | ||
| Q1 25 | -45.1% | 12.8% | ||
| Q4 24 | 7.6% | — | ||
| Q3 24 | 14.3% | — | ||
| Q2 24 | -5.7% | 16.1% | ||
| Q1 24 | -47.1% | — |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $-0.19 | — | ||
| Q1 25 | $-0.10 | — | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.03 | — | ||
| Q2 24 | $-0.01 | — | ||
| Q1 24 | $-0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $364.4M | — |
| Total DebtLower is stronger | $344.0M | — |
| Stockholders' EquityBook value | $1.3B | — |
| Total Assets | $1.9B | — |
| Debt / EquityLower = less leverage | 0.27× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $364.4M | — | ||
| Q3 25 | $412.0M | — | ||
| Q2 25 | $267.3M | — | ||
| Q1 25 | $428.8M | — | ||
| Q4 24 | $426.6M | — | ||
| Q3 24 | $400.1M | — | ||
| Q2 24 | $40.6M | — | ||
| Q1 24 | $75.6M | — |
| Q4 25 | $344.0M | — | ||
| Q3 25 | $344.2M | — | ||
| Q2 25 | $343.3M | — | ||
| Q1 25 | $439.2M | — | ||
| Q4 24 | $437.2M | — | ||
| Q3 24 | $441.0M | — | ||
| Q2 24 | $201.9M | — | ||
| Q1 24 | $350.1M | — |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.3B | — |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | 0.27× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | 0.33× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $-25.9M | — |
| Free Cash FlowOCF − Capex | $-28.6M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 1.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-190.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.9M | — | ||
| Q3 25 | $-34.6M | — | ||
| Q2 25 | $-83.4M | — | ||
| Q1 25 | $-34.6M | — | ||
| Q4 24 | $-44.4M | — | ||
| Q3 24 | $-77.1M | — | ||
| Q2 24 | $-26.4M | — | ||
| Q1 24 | $-35.6M | — |
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-37.8M | — | ||
| Q2 25 | $-86.7M | — | ||
| Q1 25 | $-37.7M | — | ||
| Q4 24 | $-49.8M | — | ||
| Q3 24 | $-85.0M | — | ||
| Q2 24 | $-33.7M | — | ||
| Q1 24 | $-40.0M | — |
| Q4 25 | -19.3% | — | ||
| Q3 25 | -24.9% | — | ||
| Q2 25 | -55.3% | — | ||
| Q1 25 | -25.2% | — | ||
| Q4 24 | -27.1% | — | ||
| Q3 24 | -49.0% | — | ||
| Q2 24 | -18.5% | — | ||
| Q1 24 | -23.0% | — |
| Q4 25 | 1.8% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 4.6% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 2.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | -1.60× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.17× | — | ||
| Q3 24 | -3.10× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OPK
| Services | $71.1M | 48% |
| Transfer Of Intellectual Property And Other | $33.7M | 23% |
| IE | $22.1M | 15% |
| Rayaldee | $8.8M | 6% |
| Barda Agreement | $6.8M | 5% |
| MX | $6.3M | 4% |
OPRA
Segment breakdown not available.